ISO 9001:2015 Certified
Live Customer Support
4.5/5 on Trustpilot
100% Quality Guarantee

Lupartumab Biosimilar - Anti-LYPD3 Antibody - Low endotoxin, Azide free (A323564)

Recombinant human monoclonal antibody to LYPD3 for ELISA, FACS, Functional Assay and In Vivo.

Shipping Information

$40
Dispatched from St. Louis, MO.
Lead Time: 12-18 business days.
Name
Lupartumab Biosimilar - Anti-LYPD3 Antibody - Low endotoxin, Azide free
Description
Recombinant human monoclonal antibody to LYPD3.
Applications
ELISA, FACS, Functional Assay, In Vivo
Reactivity
Human, Mouse, Cynomolgus Macaque
Host
Human
Clonality
Monoclonal
Isotype
IgG1
Light Chains
lambda
Conjugate

Unconjugated

Purification
Protein A affinity chromatography.
Concentration
Reconstitution dependent.
Molecular Weight
This antibody has a predicted MW of 145 kDa.
Purity
> 95% (by SDS-PAGE).
Product Form
Lyophilized
Reconstitution
Reconstitute with 100µl of sterile double-distilled water to bring antibody to 1mg/ml concentration. Gently shake to solubilize completely. Do not vortex!
Formulation
Lyophilized from 25mM Histadine, pH 6.2, with 8% Sucrose and 0.01% Tween80.
Storage
Shipped at 4°C. Lyophilized: Store at -20°C to -80°C. Reconstituted: Aliquot and store at -80°C. Product is stable for one year. Avoid freeze/thaw cycles.
Synonyms
C4.4A, GPI-anchored metastasis-associated protein C4.4A homolog, Ly6/PLAUR domain-containing protein 3, Matrigel-induced gene C4 protein, MIG-C4
Disclaimer
This product is for research use only. It is not intended for diagnostic or therapeutic use.
Publishing research using Lupartumab Biosimilar - Anti-LYPD3 Antibody - Low endotoxin, Azide free (A323564)? Please let us know so that we can list the citation on this page.

Alternative products to Lupartumab Biosimilar - Anti-LYPD3 Antibody - Low endotoxin, Azide free (A323564)

Proteins predicted to interact with LYPD3

Predicted protein interactions based upon String database. Revelancy score correlates with probability of interaction.
98.4% Relevancy Score
91.4% Relevancy Score
75.6% Relevancy Score
70.4% Relevancy Score
55.9% Relevancy Score
55.5% Relevancy Score
53.6% Relevancy Score
52.5% Relevancy Score
52.2% Relevancy Score